Drug
ABT-414
ABT-414 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
unknown125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
NCT02590263
unknown
Expanded Access to ABT-414
NCT03123952
completedphase_1
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
NCT01800695
completedphase_1
A Study of ABT-414 in Subjects With Solid Tumors
NCT01741727
Clinical Trials (4)
Showing 4 of 4 trials
NCT02590263Phase 1
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
NCT03123952
Expanded Access to ABT-414
NCT01800695Phase 1
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
NCT01741727Phase 1
A Study of ABT-414 in Subjects With Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4